Press Release

Kite Pharma – $410 Million Shelf‑Takedown Offering

March 22, 2017

San Francisco – March 22, 2017 – Cooley advised Kite Pharma on its $409.7 million shelf-takedown offering of 5,462,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase 712,500 additional shares.

Jefferies acted as the sole book-running manager for the offering. Cowen and Company, RBC Capital Markets and Guggenheim Securities acted as co-managers.

Kite Pharma, which trades on The NASDAQ Global Select Market as “KITE,” is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to target and kill cancer cells.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.